Pembrolizumab, as a monotherapy or in combination (KEYNOTE-028 and KEYNOTE-199), induces durable objective responses, with minimal adverse events, and leads to anti-tumor activity with durable clinical responses and significant OS in patients with advanced PD-L1-positive mCRPC; therefore, it has been suggested as a form of immunotherapy. Here, CD274 is linked to neoplasm.